Literature DB >> 15735798

Clinical phenotypes and factor VII genotype in congenital factor VII deficiency.

Guglielmo Mariani1, Falko H Herrmann, Alberto Dolce, Angelika Batorova, Daniela Etro, Flora Peyvandi, Karin Wulff, Jean F Schved, Günter Auerswald, Jorgen Ingerslev, Francesco Bernardi.   

Abstract

To investigate the relationship between clinical phenotype, clotting activity (FVIIc) and FVII genotype, a multi-center study of factor VII (FVII) congenital deficiency with centralized genotyping and specific functional assays was carried out. FVII mutations characterized in patients (n=313) were extremely heterogeneous (103 different, 22 novel). Clinical phenotypes ranged from asymptomatic condition, including 15 homozygotes and 14 double heterozygotes, to patients with a severe disease characterized by life-threatening and disabling symptoms (CNS, GI bleeding and hemarthrosis) strongly associated with an early age of presentation. Based on type and number of symptoms we classified 90 'severe' (median FVIIc 1.4%, IQR [Interquartile Range] 0.9-3.8), 83 'moderate' (FVIIc 3%, IQR 1-21.7), and 140 'mild' bleeders (FVIIc 14%, IQR 3-31). The significantly different FVIIc levels, and the decreasing prevalence of homozygotes or double heterozygotes among severe (98%), moderate (84%) and mild (56%) bleeders, further support our classification. The excess of females among moderate bleeders (female/male ratio = 2.6) is attributable to menorrhagia. There was no evidence for modulation of clinical features by frequent functional polymorphisms. Homozygotes for the same mutation (Ala294Val; 11125delC) with similar FVIIc and FXa generation levels, showed striking differences in clinical phenotypes. Our study depicts the ample clinical picture of this rare disorder, proposes a severity classification and provides arguments for the early management of the disease in the severe cases. Genotype-phenotype relationships indicate the presence of major environmental and/or extragenic components modulating expressivity of FVII deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735798     DOI: 10.1160/TH04-10-0650

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  37 in total

1.  Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.

Authors:  Thomas J Cramer; Kristin Anderson; Karanjia Navaz; Justin M Brown; Laurent O Mosnier; Annette von Drygalski
Journal:  Blood Cells Mol Dis       Date:  2015-11-10       Impact factor: 3.039

Review 2.  Blood coagulation factor XII--a neglected player in stroke pathophysiology.

Authors:  Mirko Pham; Guido Stoll; Bernhard Nieswandt; Martin Bendszus; Christoph Kleinschnitz
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

3.  Canine specific ELISA for coagulation factor VII.

Authors:  Tom Knudsen; Mads Kjelgaard-Hansen; Mikael Tranholm; Bo Wiinberg; Jes T Clausen; Jens Jacob Hansen; Timothy C Nichols; Marianne Kjalke; Asger L Jensen; Annemarie T Kristensen
Journal:  Vet J       Date:  2011-01-08       Impact factor: 2.688

4.  Surgery in patients with congenital factor VII deficiency: A single center experience.

Authors:  Shin-Hee Kim; Young Shil Park; Kee-Hwan Kwon; Jae Hoon Lee; Kwang Chul Kim; Myung Chul Yoo
Journal:  Korean J Hematol       Date:  2012-12-24

5.  Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

Authors:  Naoko Miyata; Mitsuhiro Isaka; Hideaki Kojima; Tomohiro Maniwa; Shoji Takahashi; Osamu Takamiya; Yasuhisa Ohde
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-24

Review 6.  Is prophylaxis required for delivery in women with factor VII deficiency?

Authors:  L M Baumann Kreuziger; Colleen T Morton; Mark T Reding
Journal:  Haemophilia       Date:  2013-04-22       Impact factor: 4.287

7.  Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).

Authors:  Mariasanta Napolitano; Muriel Giansily-Blaizot; Alberto Dolce; Jean F Schved; Guenter Auerswald; Jørgen Ingerslev; Jens Bjerre; Carmen Altisent; Pimlak Charoenkwan; Lisa Michaels; Ampaiwan Chuansumrit; Giovanni Di Minno; Umran Caliskan; Guglielmo Mariani
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

8.  Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators.

Authors:  Cristiano Bertolucci; Nicola Cavallari; Ilaria Colognesi; Jacopo Aguzzi; Zheng Chen; Pierpaolo Caruso; Augusto Foá; Gianluca Tosini; Francesco Bernardi; Mirko Pinotti
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

Review 9.  Rare congenital bleeding disorders.

Authors:  Massimo Franchini; Giuseppe Marano; Simonetta Pupella; Stefania Vaglio; Francesca Masiello; Eva Veropalumbo; Vanessa Piccinini; Ilaria Pati; Liviana Catalano; Giancarlo Maria Liumbruno
Journal:  Ann Transl Med       Date:  2018-09

10.  Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency.

Authors:  Lara Rizzotto; Mirko Pinotti; Paolo Pinton; Rosario Rizzuto; Francesco Bernardi
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.